Minal A. Barve

Minal A. Barve

Oncology | Hematology | Internal Medicine

8196 Walnut Hill Ln
Ste 100
Dallas, TX 75231

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: September 02, 2026

Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.

Correction: First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.

Journal: Journal of hematology & oncology

Published: August 11, 2026

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

Journal: The New England journal of medicine

Published: May 06, 2026

Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

Journal: Journal for immunotherapy of cancer

Published: March 26, 2026

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

Journal: Nature medicine

Published: November 25, 2025

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Journal: The Lancet. Haematology

Published: September 18, 2025

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial.

Journal: Signal transduction and targeted therapy

Published: September 05, 2025

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.

Journal: Journal of hematology & oncology

Published: July 19, 2025

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.

Journal: Nature medicine

Published: June 23, 2025

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 03, 2025

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 03, 2025

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.

Journal: Journal for immunotherapy of cancer

Published: February 03, 2025

Showing 1-12 of 58

Last Updated: 09/26/2026